Movalis (Meloxicam)

Meloxicam selectively inhibits the cyclooxygenase‑2 (COX‑2) enzyme, reducing the production of prostaglandins that mediate inflammation, pain, and fever. By lowering prostaglandin levels, it diminishes swelling and discomfort in affected tissues.

The appropriate dose of Movalis is determined by the prescribing healthcare professional based on the patient’s condition, age, renal function and other clinical factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

The safety of meloxicam in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and only under medical supervision.

To request Movalis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Movalis (meloxicam) offers once‑daily dosing and a higher selectivity for COX‑2, which may reduce gastrointestinal irritation compared with non‑selective NSAIDs like ibuprofen. However, individual response and safety profiles vary, so clinicians choose the agent best suited to the patient’s risk factors and therapeutic needs.

Store Movalis at ambient temperature, below 25 °C (77 °F). Keep the tablets in their original packaging, protect them from moisture, heat and direct sunlight to maintain product stability.

Movalis is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may lessen stomach upset. The exact administration schedule should follow the prescriber’s directions.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe skin reactions, and liver injury. Patients should be monitored for signs of these conditions and seek immediate medical attention if they occur.

Movalis is contraindicated in individuals with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal ulceration or bleeding, severe heart failure, and patients who have had a recent coronary artery bypass graft. It should also be avoided in patients with significant renal or hepatic impairment unless specifically directed by a physician.